Market price analysis and therapeutic application of genuine neratinib/neratinib

Neratinib/Neratinib is a type of targeted therapy drug. Its core mechanism of action is to lock the HER2 protein to prevent the division and growth of cancer cells. For those patients with HER2-positive breast cancer, the emergence of neratinib undoubtedly brings them new treatment hope. The pharmacological properties of neratinib enable it to bind tightly to the epidermal growth factor receptor (EGFR), HER2 and HER4, thereby achieving irreversible inhibition.

In clinical practice, oral neratinib can effectively inhibit the growth of tumor cell lines expressing HER2 and EGFR in mouse xenograft models. Neratinib is usually taken as an oral tablet, and its administration is closely related to the treatment regimen. For patients taking it alone to treat breast cancer, neratinib is usually taken with food and continued for one year. When neratinib is used in combination with capecitabine to treat advanced or spread breast cancer, patients need to take it with food every day on days 1 to 21 of a 21-day cycle until the condition changes or side effects worsen.

In the domestic market, the original drug neratinib has been successfully launched and has entered the scope of Class B medical insurance. However, medical insurance reimbursement is limited to patients who meet the indications, and the price is still high. The price of each box of neratinib, which is 40mg*180 tablets, is about RMB 7,000. This remains a significant financial burden for many patients. In comparison, the original drug Neratinib marketed overseas is more expensive, with the price per box likely to be as high as more than 10,000 US dollars. This price difference is mainly due to factors such as economic levels, medical systems, and market competition in different countries and regions.